Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Genetics Reports Uptick in Q3 Revenues

NEW YORK, Nov. 12 (GenomeWeb News) – Paradigm Genetics today reported $6 million in revenues for the third quarter of 2003, up slightly from the $5.2 million in revenues for the same period last year.

The company’s net losses decreased to $2.2 million, from $3.9 million in the year-ago quarter.

R&D expenses came to $6.2 million, compared to $6.0 million for the same period last year.

As of Sept. 30, the company had $9.9 million in cash, cash equivalents, and short-term investments.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.